Good morning readers and welcome new subscribers. It's been almost a year since we've been in touch but we are coming back in full swing with a surprise momentum alert!
It should be exactly 9:35 if there were no email delays and we want you to add this company to the top of your Friday watchlist immediately.
Our Friday momentum play is GBSN - Great Basin Scientific Inc.
Yesterday, GBSN closed with a last price of $1.94
Great Basin Scientific, Inc., a molecular diagnostics company, develops and manufactures test kits and analyzers for a patented molecular diagnostic system.
GBSN has a relatively small float of 1.36M shares according to Finviz! That is extremely small for a Nasdaq (in our opinion) With around 5M shares outstanding, it's no wonder GBSN has already proved it can fly in the past! Not too long ago GBSN went on a massive one day tear from $2 all the way to $3.
GBSN just announced growing revenues for 2014 as well:
For the 12 months ended December 31, 2014 revenue was $1.6M, an increase of 111.2% compared to $760K for the 12 months ended December 31, 2013.
In the fourth quarter of 2014, revenue was $445K, an increase of 50.5% compared to $295K in the fourth quarter of 2013.
Company Snapshot:
GBSN - a molecular diagnostics company, develops and manufactures test kits and analyzers for a patented molecular diagnostic system used in single pathogen tests. The company provides a medical diagnostic test for the detection of Clostridium difficile, a gram-positive bacteria that causes diarrhea and other intestinal disorders.
The company sells its diagnostic tests through a direct sales force in the United States, as well as through distributors in the European Union and New Zealand.
GBSN states "Our platform provides results in 45 to 115 minutes depending on the test. Molecular testing generally reduces test time from days to hours, and provides more accurate results, leading to shortened hospital stays and improved patient outcomes, all of which leads to reduced cost for hospitals that implement molecular testing in their labs."
FDA Approval Pending? Pending Catalyst.
PDUFA / normal FDA decisions are typically for drugs.
510(k) decisions are for medical devices, and GBSN could announce the results of their 510(k) submission any day now. Read this excerpt from their 2014 annual report:
In addition to our C. diff assay, we have developed a Group B Strep assay for which we filed a 510(k) submission to the FDA in the fourth quarter of 2014 and expect to receive the results of the FDA's review during the second quarter of 2015.
Will this new product boost revenue?
In the company's latest annual report, we came across another interesting excerpt.
As of December 31, 2014, we only have one commercial product, our C. diff assay and the average price has not materially changed since its commercial release.
We have 106 customers worldwide, who use an aggregate of 220 analyzers
We believe our revenue from the sale of our assays will increase as we expand our sales and marketing efforts and as we introduce new assays into the market.
We want all readers to glue GBSN to their watchlist immediately.
We believe the low float, 100% increase in revenues, and pending FDA decision warrant this ticker a TOP SPOT on our watchlist for the days ahead. Not only that, but if the company has just one product, and a second one gets approved, their sales could potentially end up even better than last year's 100% increase!
You can find tons of more info on the company's website.
Begin your research and pull up GBSN live quotes right now!
